Boston Scientific Corporation  (BSX)
Other Ticker:  
Price: $76.7600 $-0.20 -0.260%
Day's High: $77.03 Week Perf: -0.85 %
Day's Low: $ 76.43 30 Day Perf: 3.1 %
Volume (M): 3,541 52 Wk High: $ 77.64
Volume (M$): $ 271,769 52 Wk Avg: $59.90
Open: $76.85 52 Wk Low: $48.35

 Market Capitalization (Millions $) 113,735
 Shares Outstanding (Millions) 1,482
 Employees 41,000
 Revenues (TTM) (Millions $) 14,709
 Net Income (TTM) (Millions $) 1,771
 Cash Flow (TTM) (Millions $) 1,734
 Capital Exp. (TTM) (Millions $) 779

Boston Scientific Corporation
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties, including interventional cardiology, peripheral interventions, neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology, urology and gynecology. Since the Company was formed in 1979, it has advanced the practice of less-invasive medicine by providing a broad portfolio of innovative products, technologies and services across a wide range of medical specialties. The Companys products are generally inserted into the human body through natural openings or small incisions in the skin and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. These products help physicians and other medical professionals improve their patients quality of life by providing alternatives to surgery.

The Companys broad innovative product offerings have enabled it to become a leader in the interventional cardiology market. Leadership is in part due to its coronary stent product offerings. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease and implanted in patients to prop open arteries and facilitate blood flow from the heart. The Company, however, looked to further enhance the outcomes associated with the use of coronary stents, particularly the processes that lead to in-stent restenosis (the growth of neointimal tissue within an artery after angioplasty and stenting), through dedicated internal and external product development and scientific research. The Company believes that the combination of certain drugs and coronary stents offers the opportunity for a more lasting solution for coronary artery disease.

The Companys products are offered for sale by two dedicated business groups - Cardiovascular and Endosurgery. The Cardiovascular organization focuses on products and technologies for use in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery organization focuses on products and technologies for use in oncology, endoscopy, urology and gynecology procedures.

Boston Scientific announced a master branding initiative. This initiative marks the Companys evolution from a collection of divisional identities into one, unified organization. The master brand will enable the Company to strengthen recognition of the Boston Scientific name and build equity in that name.

The Company sold its products to over 10,000 hospitals, clinics, out-patient facilities and medical offices. The Company is not dependent on any single institution

The Company also distributes certain products for third parties, including an introducer sheath, certain guidewires and acellular tissue for use in connection with urology and gynecology procedures.


Internationally, the Company operates through three business segments divided among the geographic regions of Europe, Japan and Inter-Continental.


The Company encounters significant competition across its product lines and in each market in which its products are sold from various entities, some of which may have greater financial and marketing resources than the Company. The Companys primary competitors include: Abbott Laboratories, Inc., Cook, Inc., Guidant Corporation (including its subsidiary Advanced Cardiovascular Systems, Inc.), Johnson & Johnson (including its subsidiary, Cordis Corporation), and Medtronic, Inc. (including its subsidiary, Medtronic AVE, Inc.), as well as a wide range of companies which sell a single or limited number of competitive products or participate only in specific market segment.

   Company Address: 300 Boston Scientific Way Marlborough 1752 MA
   Company Phone Number: 683-4000   Stock Exchange / Ticker: NYSE BSX

Customers Net Income grew by BSX's Customers Net Profit Margin grew to

30.13 %

2.94 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
EW        1.38% 
SYK   -0.92%    
ABT   -3.54%    
DHR   -3.71%    
JNJ   -1.08%    
KNW        20.66% 
• View Complete Report

Boston Scientific Corporation

Strategic Partnerships and Strong Financial Performance Drive Boston Scientific's Success in Q1 2024

Boston Scientific Corporation, a leading player in the global medical technology sector, has recently reported its financial results for the first quarter of 2024. The company showcased impressive performance, witnessing substantial increases in profitability, revenue, and net earnings. Additionally, Boston Scientific has expanded its strategic partnership with Scivita Medical Technology Co., Ltd., emphasizing the growing demand for advanced medical devices globally. The company's shares have also experienced positive gains, further highlighting its strength in the market.
Financial Highlights:
1. Profitability: Boston Scientific witnessed a jump in profitability, with earnings per share increasing by 57.14% to $0.33 in Q1 2024, compared to the prior year period's $0.30 per share.
2. Revenue Boost: The company's revenue surged by 13.809% to reach $3.86 billion in Q1 2024, outperforming its industry peers, who reported an average business improvement of 5.79% during the same period.
3. Favorable Comparative Growth: Compared to the previous reporting period, the company's income improved by 8.93%, and revenue surged by 3.544%.
4. Net Earnings: Boston Scientific's bottom-line grew significantly, with net earnings reaching $493 million in Q1 2024, a year-on-year increase of 57.01% from the $314 million reported in the same period the previous year.
5. Profit Margin: Boston Scientific highlighted its improving profit margins, with the net margin rising to 12.78% and the operating margin edging up to 17.5% in Q1 2024.


Scivita Medical and Boston Scientific Foster Strong Collaboration Amidst Growing Healthcare Industry

Published Tue, Mar 26 2024 1:30 AM UTC

In a recent move, Scivita Medical Technology Co., Ltd. (Scivita Medical) and Boston Scientific Corporation (NYSE: BSX) have further solidified their strategic partnership in the global medical technology sector. The expanded collaboration between the two leading healthcare companies reflects the increasing demand for innovative solutions and advanced medical devices worldwid...


Axonics Stockholders Approve Merger Agreement with Boston Scientific as Company Outperforms Competitors

Published Fri, Mar 22 2024 8:01 PM UTC

In a significant development for the medical technology industry, Axonics, Inc. announced that its stockholders have voted in favor of adopting the merger agreement with Boston Scientific Corporation. This decision marks a crucial step towards solidifying the partnership and signifies the market's confidence in the potential benefits that lie ahead. Moreover, amidst a challe...

Stock Offering

Boston Scientific's $2 Billion Senior Notes Offering: Empowering Innovation in Healthcare

Published Fri, Feb 23 2024 2:27 AM UTC

Boston Scientific Corporation (NYSE: BSX), a leading medical technology company, has announced the successful pricing of $2 billion in senior notes by its wholly owned finance subsidiary, American Medical Systems Europe B.V. This significant offering demonstrates the company's robust financial position and signals its continued commitment to innovation and growth i...

Boston Scientific Corporation

Boston Scientific Corporation Makes Giant Leap in Urology with $3.7 Billion Acquisition

Axonics, Inc.'s definitive agreement to be acquired by Boston Scientific Corporation for the impressive sum of $3.7 billion marks a significant milestone in the field of urology medical devices. This game-changing deal is set to reshape the landscape of sacral neuromodulation therapy for bladder and bowel dysfunction, solidifying Boston Scientific's position in the market and expanding its product portfolio. With a strong commitment to innovation and improving patient outcomes, Boston Scientific's acquisition of Axonics is poised to drive advancements in urology medical devices and ultimately benefit patients worldwide.
Boston Scientific Corporation, known for its dedication to research and development, operates with a business model focused on designing, developing, and manufacturing a wide range of medical devices across various medical specialties. With a global presence and robust sales and distribution networks, the company is able to effectively deliver its products to healthcare professionals and hospitals around the world. Boston Scientific's emphasis on introducing cutting-edge technologies and solutions to the market has positioned it as a leader in the medical device industry.


Boston Scientific's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Cardiac Rhythm Management
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Boston Scientific announced annual revenue outlook on

Earnings Outlook
Boston Scientific Corporation issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific
Other countries


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com